Your browser doesn't support javascript.
loading
Assessing the risk of drug crystallization in vivo.
Ruepp, Stefan; Janovitz, Evan; Brodie, Thomas; White, Randy; Santella, Joseph; Hynes, John; Carman, Julie; Pan, Duohai; Wu, Yang; Hanumegowda, Umesh; Gemzik, Brian; Megill, John; DiPiero, Janet; Drexler, Dieter; Su, Ching-Chiang; Hageman, Michael.
Afiliação
  • Ruepp S; Research & Development, Bristol-Myers Squibb Company, Princeton, NJ, USA. Electronic address: stefan.ruepp@bms.com.
  • Janovitz E; Research & Development, Bristol-Myers Squibb Company, Princeton, NJ, USA.
  • Brodie T; Research & Development, Bristol-Myers Squibb Company, New Brunswick, NJ, USA.
  • White R; Research & Development, Bristol-Myers Squibb Company, New Brunswick, NJ, USA.
  • Santella J; Research & Development, Bristol-Myers Squibb Company, Princeton, NJ, USA.
  • Hynes J; Research & Development, Bristol-Myers Squibb Company, Princeton, NJ, USA.
  • Carman J; Research & Development, Bristol-Myers Squibb Company, Princeton, NJ, USA.
  • Pan D; Research & Development, Bristol-Myers Squibb Company, New Brunswick, NJ, USA.
  • Wu Y; Research & Development, Bristol-Myers Squibb Company, Wallingford, CT, USA.
  • Hanumegowda U; Research & Development, Bristol-Myers Squibb Company, Wallingford, CT, USA; ViiV Healthcare, Wallingford, CT, USA.
  • Gemzik B; Research & Development, Bristol-Myers Squibb Company, Princeton, NJ, USA.
  • Megill J; Research & Development, Bristol-Myers Squibb Company, Princeton, NJ, USA.
  • DiPiero J; Research & Development, Bristol-Myers Squibb Company, Princeton, NJ, USA.
  • Drexler D; Research & Development, Bristol-Myers Squibb Company, Wallingford, CT, USA.
  • Su CC; Research & Development, Bristol-Myers Squibb Company, Princeton, NJ, USA.
  • Hageman M; Research & Development, Bristol-Myers Squibb Company, Princeton, NJ, USA; University of Kansas, Lawrence, KS, USA.
Article em En | MEDLINE | ID: mdl-30553974
ABSTRACT

INTRODUCTION:

Low intrinsic solubility leading to poor oral bioavailability is a common challenge in drug discovery that can often be overcome by formulation strategies, however, it remains a potential limitation that can pose challenges for early risk assessment and represent a significant obstacle to drug development. We identified a selective inhibitor (BMS-986126) of the IL-1 receptor-associated kinase 4 (IRAK4) with favorable properties as a lead candidate, but with unusually low intrinsic solubility of <1 µg/mL.

METHODS:

Conventional histopathology identified the issue of crystal formation in vivo. Subsequent investigative work included confocal Raman micro-spectroscopy, MALDI-MS, polarized light microscopy of fresh wet-mount tissue scrapings and transmission electron microscopy.

RESULTS:

BMS-986126 was advanced into a 2-week toxicology study in rats. The main finding in this study was minimal granulomatous inflammation in the duodenum, associated with the presence of birefringent crystals at the highest dosage of 100 mg/kg/day. Considering the safety margin, and the single location of the lesion, BMS-986126 was further progressed into IND-enabling toxicology studies where tolerability deteriorated with increasing dosing duration. Birefringent crystals and granulomatous inflammation were detected in multiple organs at dosages ≥20 mg/kg/day. Raman spectroscopy confirmed the identity of the crystals as BMS-986126. Therefore, follow up investigations were conducted to further characterize drug crystallization and to evaluate detection methods for their potential to reliably detect in vivo crystallization early.

DISCUSSION:

The purpose of our efforts was to identify critical factors influencing in vivo drug crystallization and to provide a preliminary assessment (based on one compound) which method would be best suited for identifying crystals. Results indicated a combination of methods was required to provide a complete assessment of drug crystallization and that a simple technique, scraping of freshly collected tissue followed by evaluation under polarizing light was suitable for detecting crystals. However, dosing for 2 weeks was required for crystals to grow to a clearly detectable size.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazóis / Piridinas / Cristalização / Quinases Associadas a Receptores de Interleucina-1 Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Animals Idioma: En Revista: J Pharmacol Toxicol Methods Assunto da revista: FARMACOLOGIA / TOXICOLOGIA Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazóis / Piridinas / Cristalização / Quinases Associadas a Receptores de Interleucina-1 Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Animals Idioma: En Revista: J Pharmacol Toxicol Methods Assunto da revista: FARMACOLOGIA / TOXICOLOGIA Ano de publicação: 2019 Tipo de documento: Article